These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 2449299)

  • 1. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
    Lucore CL; Sobel BE
    Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
    Lucore CL; Fujii S; Sobel BE
    Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.
    Bennett B; Croll A; Ferguson K; Booth NA
    Blood; 1990 Feb; 75(3):671-6. PubMed ID: 1688722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in various parameters of fibrinolysis in persons infused with tissue plasminogen activator: special reference to plasminogen activator inhibitor.
    Takada A; Hou P; Mori T; Takada Y
    Thromb Res Suppl; 1988; 8():23-33. PubMed ID: 3144766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the fibrinolytic system components during acute myocardial infarction.
    Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
    Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.
    Alessi MC; Juhan-Vague I; Declerck PJ; Collen D
    Thromb Res; 1991 May; 62(4):275-85. PubMed ID: 1907771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
    Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
    Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
    Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
    Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
    Schleef RR; Higgins DL; Pillemer E; Levitt LJ
    J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
    Auwerx J; Bouillon R; Collen D; Geboers J
    Arteriosclerosis; 1988; 8(1):68-72. PubMed ID: 2449156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
    van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
    Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
    Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J
    Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors.
    Mukherjee M; Sembhi K; Kakkar VV
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):491-6. PubMed ID: 8840003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial changes in plasma concentration of plasminogen activator inhibitor-1 before and serially after thrombolytic therapy for acute myocardial infarction.
    Goto S; Kawai Y; Handa S; Abe S; Takahashi E; Watanabe K; Hori S; Ikeda Y
    Cardiology; 1993; 82(4):280-5. PubMed ID: 8402755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
    Sørensen JV
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurements of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma.
    Takada Y; Takada A
    Thromb Res Suppl; 1988; 8():15-22. PubMed ID: 3144765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
    Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM
    Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.